TrialCirculation2022

Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab.

Emil Hagström et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.